Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$0.49 - $0.88 $138,721 - $249,132
-283,105 Reduced 6.57%
4,026,224 $2.42 Million
Q3 2021

Nov 12, 2021

BUY
$8.56 - $27.17 $36.9 Million - $117 Million
4,309,329 New
4,309,329 $60.5 Million

Others Institutions Holding EFTR

About eFFECTOR Therapeutics, Inc.


  • Ticker EFTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,452,800
  • Description
  • eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...
More about EFTR
Track This Portfolio

Track Column Group LLC Portfolio

Follow Column Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Column Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Column Group LLC with notifications on news.